Browsing: Weight Loss

The convenience of taking a daily pill to lose weight is attracting a new group of patients to try emerging oral GLP-1 drugs such as Foundayo and Wegovy

Strict criteria, no price tag, and a 2027 filing leave plan sponsors watching from the sidelines

WOONSOCKET, R.I., August 5, 2026 — CVS Health® (NYSE: CVS) today announced a revamp of its weight management program, making it easier for eligible adults to access clinical care, navigate medication costs and get ongoing support for GLP-1 therapy

— Management to host conference call to discuss second quarter 2026 financial results and business update today at 8:00 a.m. ET —

Novo Nordisk’s CEO sought to reassure investors that its Wegovy pill can drive profitable growth despite lower prices, as investors sent the drugmaker’s shares lower following quarterly results

Novo CEO faces investor grilling after obesity drug disappointments | News24 Novo CEO faces investor grilling after obesity drug disappointments Share your Subscriber Article You have 5 articles to share every month. Send this story to a friend! Loading, please wait… 0:00Ozempic manufacturer Novo Nordisk faces challenges as the patent on semaglutide expire in one…

GLP-1 drugs such as Ozempic have transformed healthcare in recent years, dramatically altering how we treat conditions like type 2 diabetes and obesity

Pfizer has halted a trial of an obesity drug that applied D&D Pharmatech’s (347850) oral peptide platform “Oralink.”

GLP-1 drugs were supposed to disrupt the fitness industry. Cult.fit sees them as its next growth engine – The South First | News, Politics, Sports, Entertainment & Live Updates ${author.name} `; }); } else { authorsHTML = `

A few years ago when I was visiting my mother’s house and going through boxes of things from my childhood, I came across a planner I’d had in high school